SCHEMBL1982133

SCHEMBL1982133

CC1OCC1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22182172 0.82
SCHEMBL21898926 0.76 GBA1 (0.35)
SCHEMBL16638848 0.75 OGA (0.36)
SCHEMBL1592251 0.74
SCHEMBL13347779 0.74
SCHEMBL26906395 0.74
SCHEMBL10626939 0.74
SCHEMBL28240655 0.72
SCHEMBL15759460 0.71 THRB (0.38)
SCHEMBL21699136 0.71 THRB (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111465660-A Use of multifunctional ligands for improving performance and stability of quantum dot inks 纳米系统公司 2020-07-28 CN claimed
US-20260132109-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2026-05-14 US disclosed
US-12503436-B2 Compounds and compositions for treating conditions associated with STING activity NOVARTIS PHARMA AG (CH) 2025-12-23 US disclosed
CN-119317487-A Process for preparing double metal cyanide catalysts 科思创德国股份有限公司 2025-01-14 CN disclosed
EP-4384503-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM Due, Inc. (US) 2024-06-19 EP disclosed
CN-118119595-A Compounds and compositions for the treatment of diseases associated with STING activity 艾福姆德尤股份有限公司 2024-05-31 CN disclosed
CN-111164129-B PEG-based ligands with enhanced dispersibility and improved properties 昭荣化学工业株式会社 2024-03-12 CN disclosed
CN-116332961-A Substituted heteroaryl compounds, compositions and uses thereof 广东东阳光药业有限公司 2023-06-27 CN disclosed
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed
US-7659413-B2 (Meth) acryloyl group-containing oxetane compound and production method thereof SHOWA DENKO K.K. (JP) 2010-02-09 US disclosed
EP-1713787-B1 (METH) ACRYLOYL GROUP-CONTAINING OXETANE COMPOUND AND PRODUCTION METHOD THEREOF SHOWA DENKO KK (JP) 2009-12-30 EP disclosed
WO-2009055331-A2 BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 SCHERING CORPORATION (US) 2009-04-30 WO disclosed
US-20070060760-A1 (Meth) acryloyl group-containing oxetane compound and production method thereof SHOWA DENKO K.K. (JP) 2007-03-15 US disclosed
EP-1713787-A2 (METH) ACRYLOYL GROUP-CONTAINING OXETANE COMPOUND AND PRODUCTION METHOD THEREOF SHOWA DENKO KABUSHIKI KAISHA (JP) 2006-10-25 EP disclosed
WO-2005075445-A2 (METH) ACRYLOYL GROUP-CONTAINING OXETANE COMPOUND AND PRODUCTION METHOD THEREOF SHOWA DENKO K.K. (JP) 2005-08-18 WO disclosed
EP-1509537-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2005-03-02 EP disclosed
WO-2003090690-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2003-11-06 WO disclosed
US-6177033-B1 PRESSURIZATION THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY 2001-01-23 US disclosed
WO-1994005281-A1 PHENYLMETHYL DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LABORATORIES (US) 1994-03-17 WO disclosed